Saturday, 14 December 2019

Nektar's back pain opioid gets approval for FDA review

30 July 2018 | News

NKTR-181, a long-acting (14-hour elimination half-life) mu-opioid receptor agonist, is the first analgesic opioid to show a low incidence of specific CNS-mediated side effects

 Singapore- The FDA accepts for review Nektar Therapeutics' marketing application seeking approval for NKTR-181 for the treatment of chronic low back pain in adult patients new to opioid therapy.

The company says NKTR-181, a long-acting (14-hour elimination half-life) mu-opioid receptor agonist, is the first analgesic opioid to show a low incidence of specific CNS-mediated side effects, such as euphoria, because it is designed to have low permeability across the blood-brain barrier. Its slow rate of entry into the brain minimizes the release of dopamine which produces the feeling of euphoria.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is APAC region emerging as a leader in assistive technologies?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls